Abzena (ABZA) Research Coverage Started at Peel Hunt

Equities researchers at Peel Hunt assumed coverage on shares of Abzena (LON:ABZA) in a research report issued on Thursday. The brokerage set a “buy” rating and a GBX 42 ($0.59) price target on the stock. Peel Hunt’s target price points to a potential upside of 64.58% from the stock’s current price.

ABZA has been the subject of a number of other research reports. Numis Securities restated a “buy” rating and set a GBX 80 ($1.12) price objective on shares of Abzena in a research note on Wednesday, December 13th. FinnCap reiterated a “buy” rating and issued a GBX 70 ($0.98) target price on shares of Abzena in a research report on Tuesday, November 21st.

Shares of Abzena (LON:ABZA) traded down GBX 0.48 ($0.01) during midday trading on Thursday, reaching GBX 25.52 ($0.36). The company’s stock had a trading volume of 10,341 shares, compared to its average volume of 48,482. Abzena has a 12-month low of GBX 25 ($0.35) and a 12-month high of GBX 53 ($0.74). The firm has a market cap of $54.57 and a price-to-earnings ratio of -319.00.

TRADEMARK VIOLATION NOTICE: “Abzena (ABZA) Research Coverage Started at Peel Hunt” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/11/abzena-abza-research-coverage-started-at-peel-hunt.html.

Abzena Company Profile

Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.

Receive News & Ratings for Abzena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply